CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy

Research output: Contribution to journalArticlepeer-review

Standard

CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. / Jermyn, Michael; Davis, Scott C; Dehghani, Hamid; Huggett, Matthew T; Hasan, Tayyaba; Pereira, Stephen P; Bown, Stephen G; Pogue, Brian W.

In: Physics in Medicine and Biology, Vol. 59, No. 8, 21.04.2014, p. 1911-21.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Jermyn, M., Davis, S. C., Dehghani, H., Huggett, M. T., Hasan, T., Pereira, S. P., Bown, S. G., & Pogue, B. W. (2014). CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. Physics in Medicine and Biology, 59(8), 1911-21. https://doi.org/10.1088/0031-9155/59/8/1911

Vancouver

Author

Jermyn, Michael ; Davis, Scott C ; Dehghani, Hamid ; Huggett, Matthew T ; Hasan, Tayyaba ; Pereira, Stephen P ; Bown, Stephen G ; Pogue, Brian W. / CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy. In: Physics in Medicine and Biology. 2014 ; Vol. 59, No. 8. pp. 1911-21.

Bibtex

@article{36ececb22d2a44b5a49c7361153409b4,
title = "CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy",
abstract = "The goal of this study was to determine dominant factors affecting treatment response in pancreatic cancer photodynamic therapy (PDT), based on clinically available information in the VERTPAC-01 trial. This trial investigated the safety and efficacy of verteporfin PDT in 15 patients with locally advanced pancreatic adenocarcinoma. CT scans before and after contrast enhancement from the 15 patients in the VERTPAC-01 trial were used to determine venous-phase blood contrast enhancement and this was correlated with necrotic volume determined from post-treatment CT scans, along with estimation of optical absorption in the pancreas for use in light modeling of the PDT treatment. Energy threshold contours yielded estimates for necrotic volume based on this light modeling. Both contrast-derived venous blood content and necrotic volume from light modeling yielded strong correlations with observed necrotic volume (R² = 0.85 and 0.91, respectively). These correlations were much stronger than those obtained by correlating energy delivered versus necrotic volume in the VERTPAC-01 study and in retrospective analysis from a prior clinical study. This demonstrates that contrast CT can provide key surrogate dosimetry information to assess treatment response. It also implies that light attenuation is likely the dominant factor in the VERTPAC treatment response, as opposed to other factors such as drug distribution. This study is the first to show that contrast CT provides needed surrogate dosimetry information to predict treatment response in a manner which uses standard-of-care clinical images, rather than invasive dosimetry methods.",
keywords = "Adenocarcinoma, Humans, Organs at Risk, Pancreatic Neoplasms, Photochemotherapy, Porphyrins, Tomography, X-Ray Computed, Treatment Outcome",
author = "Michael Jermyn and Davis, {Scott C} and Hamid Dehghani and Huggett, {Matthew T} and Tayyaba Hasan and Pereira, {Stephen P} and Bown, {Stephen G} and Pogue, {Brian W}",
year = "2014",
month = apr,
day = "21",
doi = "10.1088/0031-9155/59/8/1911",
language = "English",
volume = "59",
pages = "1911--21",
journal = "Physics in Medicine and Biology",
issn = "0031-9155",
publisher = "IOP Publishing",
number = "8",

}

RIS

TY - JOUR

T1 - CT contrast predicts pancreatic cancer treatment response to verteporfin-based photodynamic therapy

AU - Jermyn, Michael

AU - Davis, Scott C

AU - Dehghani, Hamid

AU - Huggett, Matthew T

AU - Hasan, Tayyaba

AU - Pereira, Stephen P

AU - Bown, Stephen G

AU - Pogue, Brian W

PY - 2014/4/21

Y1 - 2014/4/21

N2 - The goal of this study was to determine dominant factors affecting treatment response in pancreatic cancer photodynamic therapy (PDT), based on clinically available information in the VERTPAC-01 trial. This trial investigated the safety and efficacy of verteporfin PDT in 15 patients with locally advanced pancreatic adenocarcinoma. CT scans before and after contrast enhancement from the 15 patients in the VERTPAC-01 trial were used to determine venous-phase blood contrast enhancement and this was correlated with necrotic volume determined from post-treatment CT scans, along with estimation of optical absorption in the pancreas for use in light modeling of the PDT treatment. Energy threshold contours yielded estimates for necrotic volume based on this light modeling. Both contrast-derived venous blood content and necrotic volume from light modeling yielded strong correlations with observed necrotic volume (R² = 0.85 and 0.91, respectively). These correlations were much stronger than those obtained by correlating energy delivered versus necrotic volume in the VERTPAC-01 study and in retrospective analysis from a prior clinical study. This demonstrates that contrast CT can provide key surrogate dosimetry information to assess treatment response. It also implies that light attenuation is likely the dominant factor in the VERTPAC treatment response, as opposed to other factors such as drug distribution. This study is the first to show that contrast CT provides needed surrogate dosimetry information to predict treatment response in a manner which uses standard-of-care clinical images, rather than invasive dosimetry methods.

AB - The goal of this study was to determine dominant factors affecting treatment response in pancreatic cancer photodynamic therapy (PDT), based on clinically available information in the VERTPAC-01 trial. This trial investigated the safety and efficacy of verteporfin PDT in 15 patients with locally advanced pancreatic adenocarcinoma. CT scans before and after contrast enhancement from the 15 patients in the VERTPAC-01 trial were used to determine venous-phase blood contrast enhancement and this was correlated with necrotic volume determined from post-treatment CT scans, along with estimation of optical absorption in the pancreas for use in light modeling of the PDT treatment. Energy threshold contours yielded estimates for necrotic volume based on this light modeling. Both contrast-derived venous blood content and necrotic volume from light modeling yielded strong correlations with observed necrotic volume (R² = 0.85 and 0.91, respectively). These correlations were much stronger than those obtained by correlating energy delivered versus necrotic volume in the VERTPAC-01 study and in retrospective analysis from a prior clinical study. This demonstrates that contrast CT can provide key surrogate dosimetry information to assess treatment response. It also implies that light attenuation is likely the dominant factor in the VERTPAC treatment response, as opposed to other factors such as drug distribution. This study is the first to show that contrast CT provides needed surrogate dosimetry information to predict treatment response in a manner which uses standard-of-care clinical images, rather than invasive dosimetry methods.

KW - Adenocarcinoma

KW - Humans

KW - Organs at Risk

KW - Pancreatic Neoplasms

KW - Photochemotherapy

KW - Porphyrins

KW - Tomography, X-Ray Computed

KW - Treatment Outcome

U2 - 10.1088/0031-9155/59/8/1911

DO - 10.1088/0031-9155/59/8/1911

M3 - Article

C2 - 24651456

VL - 59

SP - 1911

EP - 1921

JO - Physics in Medicine and Biology

JF - Physics in Medicine and Biology

SN - 0031-9155

IS - 8

ER -